LYB LyondellBasell Industries N.V.
Industrial Organic Chemicals · NYSE · SEC CIK 1489393 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.5%
TTM net income YoY208.4%
TTM EPS YoY206.1%
Revenue 3-yr CAGR-8.2%
Net income 3-yr CAGR-17.1%
Margins
Gross margin14.3%
Operating margin8.6%
Net margin4.1%
FCF margin7.6%
EBITDA margin13.2%
Returns
ROE11.9%
ROA3.8%
ROIC (approx.)10.8%
Asset turnover0.93x
Leverage & solvency
Liabilities / assets67.3%
Debt / equity1.02x
Current ratio1.78x
Interest coverage5.06x
Cash quality & payout
Operating cash flow / net income2.85x
Accruals ratio-7.0%
Payout ratio85.6%
Capex / revenue4.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $30.15B | $33.39B | $33.34B | $50.45B | $46.17B |
| Cost of revenue | $27.58B | $28.75B | $28.43B | $43.85B | $37.40B |
| Gross profit | $2.58B | $4.64B | $4.90B | $6.60B | $8.78B |
| R&D expense | $136.00M | $135.00M | $130.00M | $124.00M | $124.00M |
| SG&A expense | $1.61B | $1.64B | $1.54B | $1.31B | $1.25B |
| Operating income | -$420.00M | $1.92B | $2.73B | $5.10B | $6.77B |
| Interest expense | $487.00M | $481.00M | $477.00M | $287.00M | $519.00M |
| Pretax income | -$715.00M | $1.70B | $2.30B | $4.78B | $6.79B |
| Income tax | $70.00M | $259.00M | $433.00M | $882.00M | $1.16B |
| Net income | -$738.00M | $1.37B | $2.12B | $3.89B | $5.62B |
| EBITDA | $970.00M | $3.44B | $4.26B | $6.37B | $8.17B |
| EPS (basic) | -2.34 | 4.16 | 6.48 | 11.84 | 16.77 |
| EPS (diluted) | -2.34 | 4.15 | 6.46 | 11.81 | 16.75 |
| Dividends declared per share | 5.45 | 5.27 | 4.94 | 4.70 | 4.44 |
| Balance sheet | |||||
| Cash & equivalents | $3.44B | $3.39B | $3.40B | $2.16B | $1.48B |
| Short-term investments | $2.03B | $2.61B | $2.43B | $1.19B | $9.00M |
| Receivables | — | — | — | $3.39B | $4.57B |
| Inventory | $3.53B | $4.66B | $4.76B | $4.80B | $4.90B |
| Current assets | $10.87B | $12.27B | $13.15B | $11.85B | $12.22B |
| PP&E, net | $15.83B | $15.07B | $15.55B | $15.39B | $14.56B |
| Goodwill | $708.00M | $1.56B | $1.65B | $1.83B | $1.88B |
| Intangibles | $450.00M | $577.00M | $641.00M | $662.00M | $695.00M |
| Total assets | $34.00B | $35.75B | $37.00B | $36.37B | $36.74B |
| Current liabilities | $6.13B | $6.71B | $7.15B | $6.76B | $7.23B |
| Short-term debt | $226.00M | $119.00M | $117.00M | $349.00M | $362.00M |
| Long-term debt | $12.12B | $10.53B | $10.33B | $10.54B | $11.25B |
| Total debt | $12.35B | $10.65B | $10.45B | $10.89B | $11.61B |
| Total liabilities | $23.80B | $23.16B | $23.94B | $23.62B | $24.75B |
| Shareholders' equity | $10.08B | $12.46B | $12.93B | $12.62B | $11.86B |
| Net debt | $8.91B | $7.26B | $7.04B | $8.73B | $10.13B |
| Shares outstanding | 322.08M | 323.89M | 324.48M | 325.72M | 329.54M |
| Cash flow statement | |||||
| Operating cash flow | $2.26B | $3.82B | $4.94B | $6.12B | $7.70B |
| Capital expenditure | $1.88B | $1.84B | $1.53B | $1.89B | $1.96B |
| Free cash flow | $384.00M | $1.98B | $3.41B | $4.23B | $5.74B |
| Investing cash flow | -$1.78B | -$1.85B | -$1.78B | -$1.98B | -$1.50B |
| Financing cash flow | -$507.00M | -$1.90B | -$1.95B | -$3.41B | -$6.38B |
| Depreciation & amortization | $1.39B | $1.52B | $1.53B | $1.27B | $1.39B |
| Stock-based compensation | $91.00M | $91.00M | $91.00M | $70.00M | $66.00M |
| Dividends paid | $1.76B | $1.72B | $1.61B | $3.25B | $1.49B |
| Share buybacks | $201.00M | $195.00M | $211.00M | $420.00M | $463.00M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.